December #184 : Cure: Curious Cohort on Early Treatment - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

The POZ 100-Accelerating the End of AIDS

The POZ 100-The Seekers

The POZ 100-The Hunters

The POZ 100-The Defenders

The POZ 100-The Soldiers

The POZ 100-Cure All Glossary

Love is the Cure

From the Editor

More Than a Feeling

Feedback

Letters-December 2012

The POZ Q+A

Towards an HIV Cure

POZ Planet

A Very Big Kiki

Russians Deploy 'Google Bombs'

Home Alone

Say What-Paris Hilton

Back to School

What's a Buyers' Club? Matthew Knows.

iPad Video Game to Teach HIV Prevention Skills

Voices

Tried and True

Care and Treatment

One a Day to Keep Heart Attacks Away?

One Form to Rule Them All

Stribild is Here

T-Totaller

Nature's Little Helpers

GMHC Treatment Issues December 2012

Research Notes

Prevention: Selzentry Is PrEP Contender

Treatment: Dolutegravir Shows Promise

Cure: Curious Cohort on Early Treatment

Concerns: Fewer Comebacks From Heart Attacks

POZ Survey Says

Healthy Technology

POZ Heroes

Breaking Bad Cycles

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

December 2012

Cure: Curious Cohort on Early Treatment

by Tim Horn

A group of HIV-positive French individuals—14 at last count—may be yet another piece of the cure puzzle. Comprising the VISCONTI cohort, they were all started on HIV treatment within 10 weeks of becoming infected, remained on therapy for an average of three years, and have subsequently stayed off treatment for roughly six years, all the while maintaining undetectable viral loads.

They’re not “elite controllers”—they don’t have the same immunologic characteristics as those able to naturally control the infection—and their prolonged time off treatment makes them unique among other early treaters.

Have these individuals been “functionally cured,” whereby HIV is still present but effectively controlled without the need for meds? Nobody has declared them as such. But they’re a model for this approach as scientists continue to tease out what separates these individuals from the rest. 

Search: VISCONTI cohort, undetectable, functional cure

Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    acousticmat
    Oakland
    California


    Poz_Qt
    Columbus
    Ohio


    pevans
    San Francisco
    California


    pozsmith1
    East Bay
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.